

Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims

Claim 1. (original) A combination, comprising ~~an endothelin receptor antagonist~~ *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (ZD4054), or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof.

Claim 2. (cancelled).

Claim 3. (previously presented) A combination according to claim 1 wherein the EGFR TKI is selected from:

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (ZD1839);

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, or a pharmaceutically-acceptable salt thereof (linked to the code numbers CP 358774 and OSI-774 (the monomethanesulphonate salt));

6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (linked to the code numbers PD 183805 and CI 1033);

4-[(1*R*)-1-phenylethylamino]-6-(4-hydroxyphenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine (linked to the code numbers PKI-166, CGP 75166 and CGP 59326);

N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide (linked to the code numbers CL-387785 and EKB-785); and

4-(3-chloro-4-fluoroanilino)-3-cyano-6-(4-dimethylaminobut-2(E)-enamido)-7-ethoxyquinoline (EKB-569);

or a pharmaceutically acceptable salt thereof.

Claim 4. (currently amended) A combination according to claim 1 wherein ~~the endothelin receptor antagonist is selected from ZD4054, or a pharmaceutically acceptable salt thereof, and~~ the EGFR TKI is selected from ZD1839, or a pharmaceutically acceptable salt thereof.

Claim 5. (cancelled)

Claim 6. (previously presented) A pharmaceutical composition comprising a combination according to claim 1, in association with a pharmaceutically acceptable diluent or carrier.

Claim 7. (previously presented) A method of treating ovarian cancer, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a combination according to claim 1.

Claim 8. - 14. (cancelled)

Claim 15. (previously presented) The method according to claim 7 wherein the cancer is in a non-metastatic state.

Claim 16-24 (cancelled)